These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16815236)

  • 1. Nephrotoxicity as a complication of antiretroviral therapy.
    Valle R; Haragsim L
    Adv Chronic Kidney Dis; 2006 Jul; 13(3):314-9. PubMed ID: 16815236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral treatment of human immunodeficiency virus infection: update for 2003.
    Postic B; Horvath JA; Talwani R
    J S C Med Assoc; 2003 Jun; 99(6):148-53. PubMed ID: 12886699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral medications: adverse effects on the kidney.
    Jao J; Wyatt CM
    Adv Chronic Kidney Dis; 2010 Jan; 17(1):72-82. PubMed ID: 20005491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-associated nephropathy in the era of antiretroviral therapy.
    Wyatt CM; Klotman PE
    Am J Med; 2007 Jun; 120(6):488-92. PubMed ID: 17524746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients.
    Marfo K; Greenstein S
    Transplant Proc; 2009 Nov; 41(9):3796-9. PubMed ID: 19917390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
    Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
    Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic renal failure among HIV-1-infected patients.
    Mocroft A; Kirk O; Gatell J; Reiss P; Gargalianos P; Zilmer K; Beniowski M; Viard JP; Staszewski S; Lundgren JD
    AIDS; 2007 May; 21(9):1119-27. PubMed ID: 17502722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
    Kong HH; Myers SA
    Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tenofovir on renal glomerular and tubular function.
    Fux CA; Christen A; Zgraggen S; Mohaupt MG; Furrer H
    AIDS; 2007 Jul; 21(11):1483-5. PubMed ID: 17589197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists.
    Berns JS; Kasbekar N
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):117-29. PubMed ID: 17699198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir].
    de la Prada FJ; Prados AM; Tugores A; Uriol M; Saus C; Morey A
    Nefrologia; 2006; 26(5):626-30. PubMed ID: 17117909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.
    Gehrig AK; Mikus G; Haefeli WE; Burhenne J
    Rapid Commun Mass Spectrom; 2007; 21(16):2704-16. PubMed ID: 17639576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity related to new therapeutic compounds.
    Szeto CC; Chow KM
    Ren Fail; 2005; 27(3):329-33. PubMed ID: 15957551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral nephrotoxicities.
    Atta MG; Deray G; Lucas GM
    Semin Nephrol; 2008 Nov; 28(6):563-75. PubMed ID: 19013327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article.
    Petrovic LM
    Liver Int; 2007 Jun; 27(5):598-606. PubMed ID: 17498243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.